SBIR-STTR Award

Chromatid Painting for Chromosomal Inversion Detection
Award last edited on: 1/14/2016

Sponsored Program
SBIR
Awarding Agency
NASA : JSC
Total Award Amount
$699,998
Award Phase
2
Solicitation Topic Code
X13.02
Principal Investigator
Edwin Goodwin

Company Information

KromaTiD Inc

1880 Industrial Drive Suite A
Longmont, CO 80501
   (303) 775-1512
   info@kromatid.com
   www.kromatid.com
Location: Single
Congr. District: 04
County: Boulder

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2009
Phase I Amount
$99,998
We propose a novel approach to the detection of chromosomal inversions. Transmissible chromosome aberrations (translocations and inversions) have profound genetic effects, such as disrupting regulatory sequences that control gene expression, or creating genetic chimeras. These chromosome aberrations play a causative role in cancer, and they are induced by radiation. As such, chromosome aberrations are relevant to three NASA needs, biodosimetry, analysis of astronaut lymphocytes for cumulative radiation damage, and space radiation risk modeling. Of all structural chromosomal anomalies, inversions a reversal of orientation of material within a chromosome are the most difficult to detect. This is especially true of small inversions, most of which are invisible to all current cytogenetic techniques. Yet small inversions are likely the most transmissible (nonlethal) form of chromosomal damage, so they persist, a feature which lends credence to their use in retrospective biodosimetry. This Phase 1 project is intended to provide a proof-of-principle demonstration of a new method of molecular cytogenetics that will permit highly sensitive inversion detection. The project will help us to perfect our bioinformatics strategy for probe design, optimize probe labeling reactions, refine hybridization conditions, and establish a procedure for cost analysis. In Phase 2, we will scale-up probe production to make whole chromosome analysis possible. This next step, although conceptually simple, relies entirely on the processes devised and tested in Phase 1. Moreover efficient, cost-effective probe-making will be essential to commercialization (Phase 3). The technology readiness level at the end of the Phase 1 contract is expected to be 4-5, i.e. validated in laboratory and relevant environments.

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2010
Phase II Amount
$600,000
We propose the continued development of a novel approach to the detection of chromosomal inversions. Transmissible chromosome aberrations (translocations and inversions) have profound genetic effects, such as disrupting regulatory sequences that control gene expression, or creating genetic chimeras. These chromosome aberrations play a causative role in cancer, and ionizing radiation is one of the most efficient agents known to induce them. As such, chromosome aberrations are relevant to three NASA needs, biodosimetry, analysis of astronaut lymphocytes for cumulative radiation damage, and space radiation risk modeling. Of all structural chromosomal anomalies, inversions a reversal of orientation of material within a chromosome are the most difficult to detect. This is especially true of small inversions, most of which are invisible to all current cytogenetic techniques. Yet small inversions are likely the most transmissible (nonlethal) form of chromosomal damage, so they persist for long periods. This is a useful feature for retrospective biodosimetry, and may also prove to be useful as an indicator of radiation quality.. In Phase 1 we demonstrated the use of a human chromosome 3, partial chromatid paint to detect a known inversion. During Phase 2, we will continue to improve the efficiency of the technology, an essential goal for commercialization (Phase 3) ultimately creating an improved and complete chromatid paint for chromosome 3. Finally, we will test the chromosome 3 'chromatid paint's' ability to detect radiation-induced inversions, and establish their frequency. The technology readiness level at the end of the Phase 2 contract is expected to be 5, i.e. validated in laboratory and relevant environments.